{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:13:23Z","timestamp":1785413603547,"version":"3.56.0"},"posted":{"date-parts":[[2026,4,15]]},"group-title":"Neuroscience","reference-count":70,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.biorxiv.org\/about\/FAQ#license"}],"funder":[{"award":["CA196263"],"award-info":[{"award-number":["CA196263"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}]},{"award":["UL1TR007881"],"award-info":[{"award-number":["UL1TR007881"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}]},{"award":["UG3 NS128148"],"award-info":[{"award-number":["UG3 NS128148"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Shirley and Stefan Hatos Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Cannabis is increasingly used for pain management, with many patients reporting relief from chronic pain that did not respond to conventional treatments. However, cannabis is also associated with unwanted side effects including psychomimetic effects and the potential of developing a cannabis use disorder. To circumvent the central nervous system effects, we investigated whether a peripherally restricted cannabinoid receptor (CB1) agonist, PrNMI [(4-{2-[-(1E)-1[(4-propylnaphthalen-1-yl)methylidene]-1H-inden-3yl]ethyl}morpholine] attenuated pain hypersensitivity associated with nerve injury and profiled its\u2019 abuse potential.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>Mice with chronic constriction injury (CCI) of the sciatic nerve developed hypersensitivity to mechanical stimulation. Paw withdrawal thresholds were assessed following administration of PrNMI (i.p. 0.3 mg\/kg and 0.6 mg\/kg) or vehicle in CCI and sham mice. The conditioned place preference model was used to measure drug-reward to 0.6 mg\/kg i.p. PrNMI in CCI and sham-injury control animals. We further assessed abuse potential to determine if PrNMI (0.5 mg\/kg) would reinstate drug-seeking behavior in mice trained to self-administer intravenous fentanyl (10 \u03bcg\/kg\/infusion).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>PrNMI administration transiently increased paw withdrawal thresholds in mice with CCI-induced allodynia in a dose-dependent manner. PrNMI conditioning did not produce a conditioned place preference in mice with either CCI or sham injury. Mice who had learned to self-administer fentanyl and went through extinction training did not reinstate drug-seeking behavior when administered PrNMI.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>The systemic CB1 receptor agonist PrNMI demonstrated analgesic benefit in alleviating mechanical allodynia associated with chronic constriction injury of the sciatic nerve without increasing addiction related behaviors associated with the establishment of addiction.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.04.13.718281","type":"posted-content","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:05:18Z","timestamp":1776254718000},"source":"Crossref","is-referenced-by-count":0,"title":["A peripherally restricted cannabinoid 1 receptor agonist provides analgesic benefit from neuropathic pain and a lack of addiction-related behavior"],"prefix":"10.64898","author":[{"given":"Amie","family":"Severino","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, California, USA"},{"name":"Shirley and Stefan Hatos Center for Neuropharmacology, Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay M.","family":"Lueptow","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, California, USA"},{"name":"Shirley and Stefan Hatos Center for Neuropharmacology, Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, California, USA"},{"name":"Department of Psychology, University of California, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Ellis","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, California, USA"},{"name":"Shirley and Stefan Hatos Center for Neuropharmacology, Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dania","family":"Alkoraishi","sequence":"additional","affiliation":[{"name":"Laboratory of Neuropharmacology, Section of Biosystems and Function, School of Dentistry, University of California, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Spigelman","sequence":"additional","affiliation":[{"name":"Laboratory of Neuropharmacology, Section of Biosystems and Function, School of Dentistry, University of California, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6936-5524","authenticated-orcid":false,"given":"Catherine M.","family":"Cahill","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, California, USA"},{"name":"Shirley and Stefan Hatos Center for Neuropharmacology, Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026041801401344000_2026.04.13.718281v1.1","doi-asserted-by":"publisher","DOI":"10.1038\/nn1916"},{"issue":"9","key":"2026041801401344000_2026.04.13.718281v1.2","first-page":"e10436","volume-title":"Cureus","volume":"12","year":"2020"},{"key":"2026041801401344000_2026.04.13.718281v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2018.05.041"},{"issue":"1","key":"2026041801401344000_2026.04.13.718281v1.4","doi-asserted-by":"crossref","first-page":"e2249797","DOI":"10.1001\/jamanetworkopen.2022.49797","article-title":"Use of Cannabis and Other Pain Treatments Among Adults With Chronic Pain in US States With Medical Cannabis Programs","volume":"6","year":"2023","journal-title":"JAMA Network Open"},{"issue":"3","key":"2026041801401344000_2026.04.13.718281v1.5","first-page":"396","volume-title":"Journal of neurochemistry","volume":"139","year":"2016"},{"key":"2026041801401344000_2026.04.13.718281v1.6","doi-asserted-by":"publisher","DOI":"10.7326\/M22-0217"},{"key":"2026041801401344000_2026.04.13.718281v1.7","first-page":"26","volume-title":"Molecular pain","volume":"10","year":"2014"},{"key":"2026041801401344000_2026.04.13.718281v1.8","doi-asserted-by":"publisher","DOI":"10.1097\/FBP.0b013e3283618ac8"},{"key":"2026041801401344000_2026.04.13.718281v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2016.08.002"},{"issue":"1","key":"2026041801401344000_2026.04.13.718281v1.10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1940-0640-8-21","article-title":"Management of chronic pain with chronic opioid therapy in patients with substance use disorders","volume":"8","year":"2013","journal-title":"Addiction Science & Clinical Practice"},{"key":"2026041801401344000_2026.04.13.718281v1.11","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0270(94)90144-9"},{"issue":"6","key":"2026041801401344000_2026.04.13.718281v1.12","first-page":"1419","volume-title":"Psychopharmacology","volume":"242","year":"2025"},{"key":"2026041801401344000_2026.04.13.718281v1.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2018.12.005"},{"issue":"4","key":"2026041801401344000_2026.04.13.718281v1.14","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/nprot.2006.279","article-title":"Drug-induced conditioned place preference and aversion in mice","volume":"1","year":"2006","journal-title":"Nature Protocols"},{"key":"2026041801401344000_2026.04.13.718281v1.15","doi-asserted-by":"crossref","first-page":"111263","DOI":"10.1016\/j.drugalcdep.2024.111263","article-title":"The prevalence of cannabis use disorders in people who use medicinal cannabis: A systematic review and meta-analysis","volume":"257","year":"2024","journal-title":"Drug and Alcohol Dependence"},{"key":"2026041801401344000_2026.04.13.718281v1.16","doi-asserted-by":"crossref","unstructured":"Evans CJ and Cahill CM (2016) Neurobiology of opioid dependence in creating addiction vulnerability. F1000Research 5. England: F1000 Faculty Rev-1748.","DOI":"10.12688\/f1000research.8369.1"},{"key":"2026041801401344000_2026.04.13.718281v1.17","first-page":"22","volume-title":"Multiple sclerosis and related disorders","volume":"17","year":"2017"},{"issue":"10180","key":"2026041801401344000_2026.04.13.718281v1.18","first-page":"1537","volume-title":"Lancet (London, England)","volume":"393","year":"2019"},{"key":"2026041801401344000_2026.04.13.718281v1.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2020.06.006"},{"key":"2026041801401344000_2026.04.13.718281v1.20","first-page":"177","volume-title":"Advances in experimental medicine and biology","volume":"1274","year":"2020"},{"issue":"1","key":"2026041801401344000_2026.04.13.718281v1.21","first-page":"297","volume-title":"Journal of neuroscience research","volume":"100","year":"2022"},{"key":"2026041801401344000_2026.04.13.718281v1.22","unstructured":"Guide for the Care and Use of Laboratory Animals (2011) 8th edn Washington (DC)."},{"key":"2026041801401344000_2026.04.13.718281v1.23","doi-asserted-by":"crossref","unstructured":"Hakimian JK , Dong TS , Barahona JA , et al. (2019) Dietary Supplementation with Omega-3 Polyunsaturated Fatty Acids Reduces Opioid-Seeking Behaviors and Alters the Gut Microbiome. Nutrients 11(8). Switzerland.","DOI":"10.3390\/nu11081900"},{"key":"2026041801401344000_2026.04.13.718281v1.24","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-024-01880-2"},{"key":"2026041801401344000_2026.04.13.718281v1.25","doi-asserted-by":"publisher","DOI":"10.1111\/adb.13170"},{"issue":"5","key":"2026041801401344000_2026.04.13.718281v1.26","first-page":"e2970","volume-title":"Brain and behavior","volume":"13","year":"2023"},{"key":"2026041801401344000_2026.04.13.718281v1.27","doi-asserted-by":"crossref","unstructured":"Howlett AC , Thomas BF and Huffman JW (2021) The Spicy Story of Cannabimimetic Indoles. Molecules (Basel, Switzerland) 26(20). Switzerland.","DOI":"10.3390\/molecules26206190"},{"key":"2026041801401344000_2026.04.13.718281v1.28","doi-asserted-by":"crossref","unstructured":"Hryhorowicz S , Kaczmarek-Rys M , Andrzejewska A , et al. (2019) Allosteric Modulation of Cannabinoid Receptor 1-Current Challenges and Future Opportunities. International journal of molecular sciences 20(23). Switzerland.","DOI":"10.3390\/ijms20235874"},{"issue":"13","key":"2026041801401344000_2026.04.13.718281v1.29","first-page":"2948","volume-title":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","volume":"40","year":"2015"},{"key":"2026041801401344000_2026.04.13.718281v1.30","first-page":"173182","volume-title":"Pharmacology, biochemistry, and behavior","volume":"205","year":"2021"},{"key":"2026041801401344000_2026.04.13.718281v1.31","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.120.000083"},{"key":"2026041801401344000_2026.04.13.718281v1.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2008.10.001"},{"key":"2026041801401344000_2026.04.13.718281v1.33","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0274-19.2019"},{"issue":"1","key":"2026041801401344000_2026.04.13.718281v1.34","first-page":"226","volume-title":"Arthritis research & therapy","volume":"17","year":"2015"},{"key":"2026041801401344000_2026.04.13.718281v1.35","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000003606"},{"key":"2026041801401344000_2026.04.13.718281v1.36","doi-asserted-by":"crossref","unstructured":"Mackie K (2005) Distribution of cannabinoid receptors in the central and peripheral nervous system. Handbook of experimental pharmacology (168). Germany: 299\u2013325.","DOI":"10.1007\/3-540-26573-2_10"},{"issue":"2","key":"2026041801401344000_2026.04.13.718281v1.37","first-page":"119","volume-title":"further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial. The International journal of neuroscience","volume":"129","year":"2019"},{"key":"2026041801401344000_2026.04.13.718281v1.38","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-010-1974-9"},{"key":"2026041801401344000_2026.04.13.718281v1.39","doi-asserted-by":"publisher","DOI":"10.1126\/science.150.3699.971"},{"key":"2026041801401344000_2026.04.13.718281v1.40","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-019-00660-0"},{"issue":"1","key":"2026041801401344000_2026.04.13.718281v1.41","first-page":"106","volume-title":"Journal of dual diagnosis","volume":"16","year":"2020"},{"key":"2026041801401344000_2026.04.13.718281v1.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.07.002"},{"key":"2026041801401344000_2026.04.13.718281v1.43","doi-asserted-by":"publisher","DOI":"10.17226\/24625"},{"key":"2026041801401344000_2026.04.13.718281v1.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2021.108476"},{"issue":"1","key":"2026041801401344000_2026.04.13.718281v1.45","first-page":"242","volume-title":"BMC veterinary research","volume":"16","year":"2020"},{"issue":"1","key":"2026041801401344000_2026.04.13.718281v1.46","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.japh.2019.07.015","article-title":"The effects of cannabis, cannabinoids, and their administration routes on pain control efficacy and safety: A systematic review and network meta-analysis","volume":"60","year":"2020","journal-title":"Journal of the American Pharmacists Association"},{"issue":"8057","key":"2026041801401344000_2026.04.13.718281v1.47","first-page":"265","volume-title":"Nature","volume":"640","year":"2025"},{"issue":"1","key":"2026041801401344000_2026.04.13.718281v1.48","first-page":"160","volume-title":"Cannabis and cannabinoid research","volume":"2","year":"2017"},{"key":"2026041801401344000_2026.04.13.718281v1.49","doi-asserted-by":"crossref","unstructured":"Ren M and Lotfipour S (2022) Dose- and Sex-Dependent Bidirectional Relationship between Intravenous Fentanyl Self-Administration and Gut Microbiota. Microorganisms 10(6). Switzerland.","DOI":"10.3390\/microorganisms10061127"},{"key":"2026041801401344000_2026.04.13.718281v1.50","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00025.2008"},{"key":"2026041801401344000_2026.04.13.718281v1.51","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b00516"},{"key":"2026041801401344000_2026.04.13.718281v1.52","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001247"},{"key":"2026041801401344000_2026.04.13.718281v1.53","first-page":"119","volume-title":"Frontiers in psychiatry","volume":"9","year":"2018"},{"issue":"3","key":"2026041801401344000_2026.04.13.718281v1.54","first-page":"544","volume-title":"Anesthesiology","volume":"129","year":"2018"},{"issue":"24","key":"2026041801401344000_2026.04.13.718281v1.55","first-page":"e2321532121","volume-title":"Proceedings of the National Academy of Sciences of the United States of America","volume":"121","year":"2024"},{"issue":"1","key":"2026041801401344000_2026.04.13.718281v1.56","first-page":"21422","volume-title":"Scientific reports","volume":"12","year":"2022"},{"key":"2026041801401344000_2026.04.13.718281v1.57","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4036-14.2015"},{"key":"2026041801401344000_2026.04.13.718281v1.58","first-page":"108795","volume-title":"Pharmacology & therapeutics","volume":"267","year":"2025"},{"key":"2026041801401344000_2026.04.13.718281v1.59","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13989"},{"issue":"7","key":"2026041801401344000_2026.04.13.718281v1.60","first-page":"e26913","volume-title":"Cureus","volume":"14","year":"2022"},{"key":"2026041801401344000_2026.04.13.718281v1.61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1507771"},{"key":"2026041801401344000_2026.04.13.718281v1.62","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-155-5-201109060-00011"},{"issue":"10","key":"2026041801401344000_2026.04.13.718281v1.63","first-page":"1469","volume-title":"The Journal of pharmacy and pharmacology","volume":"71","year":"2019"},{"key":"2026041801401344000_2026.04.13.718281v1.64","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(85)90127-3"},{"issue":"5","key":"2026041801401344000_2026.04.13.718281v1.65","first-page":"621","volume-title":"Cannabis and cannabinoid research","volume":"7","year":"2022"},{"issue":"1","key":"2026041801401344000_2026.04.13.718281v1.66","first-page":"e897","volume-title":"Pain reports","volume":"6","year":"2021"},{"key":"2026041801401344000_2026.04.13.718281v1.67","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2021.108590"},{"key":"2026041801401344000_2026.04.13.718281v1.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.06.015"},{"key":"2026041801401344000_2026.04.13.718281v1.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2019.08.025"},{"issue":"9","key":"2026041801401344000_2026.04.13.718281v1.70","first-page":"1814","volume-title":"Pain","volume":"159","year":"2018"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.04.13.718281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T08:40:27Z","timestamp":1776501627000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.04.13.718281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":70,"URL":"https:\/\/doi.org\/10.64898\/2026.04.13.718281","relation":{},"subject":[],"published":{"date-parts":[[2026,4,15]]},"subtype":"preprint"}}